Key features and details
- Rabbit polyclonal to IFITM1
- Suitable for: ICC/IF, WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-IFITM1 antibody
See all IFITM1 primary antibodies
DescriptionRabbit polyclonal to IFITM1
Tested applicationsSuitable for: ICC/IF, WB, IHC-Pmore details
Species reactivityReacts with: Human
- IHC-P: Human epididymis. WB: CAPAN-2 cell lysate. ICC/IF: A431 cells.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.02% Sodium azide
Constituents: 40% Glycerol, PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab224063 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 0.25 - 2 µg/ml.
Fixation/Permeabilization: PFA/Triton X-100.
|WB||Use a concentration of 0.04 - 0.4 µg/ml. Predicted molecular weight: 13 kDa.|
|IHC-P||1/200 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionIFN-induced antiviral protein that mediate cellular innate immunity to at least three major human pathogens, namely influenza A H1N1 virus, West Nile virus, and dengue virus by inhibiting the early step(s) of replication. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activition or by arresting cell growth in G1 phase in a p53-dependent manner. Implicated in the control of cell growth. Component of a multimeric complex involved in the transduction of antiproliferative and homotypic adhesion signals.
Sequence similaritiesBelongs to the CD225 family.
modificationsPalmitoylation on membrane-proximal cysteines controls clustering in membrane compartments and antiviral activity against influenza virus.
Cellular localizationCell membrane.
- Information by UniProt
- 9-27 antibody
- CD 225 antibody
- CD 225 antigen antibody
Anti-IFITM1 antibody (ab224063) at 1/100 dilution + CAPAN-2 cell lysate
Predicted band size: 13 kDa
PFA-fixed, Triton X-100 permeabilized A431 (human epidermoid carcinoma cell line) cells stained for IFITM1 (green) using ab224063 (4 µg/ml) in ICC/IF.
Paraffin embedded human epididymis tissue stained for IFITM1 with ab224063 (1/200 dilution) in immunohistochemical analysis.
ab224063 has been referenced in 2 publications.
- Kim SH et al. Epigenetic regulation of IFITM1 expression in lipopolysaccharide-stimulated human mesenchymal stromal cells. Stem Cell Res Ther 11:16 (2020). PubMed: 31910882
- Yang J et al. Combination of IFITM1 knockdown and radiotherapy inhibits the growth of oral cancer. Cancer Sci 109:3115-3128 (2018). PubMed: 29770536